CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval
NewTimeSpace News: On 10 August 2026, CSPC Pharmaceutical Group (01093.HK) announced that SYS6037 Injection (monkeypox mRNA vaccine), a Class 1 new prophylactic biological product co‑developed by the Group and the Institute of Microbiology, Chinese Academy of Sciences, has obtained approval from the US FDA to carry out clinical trials.
According to the announcement, the product is a multi‑antigen monkeypox vaccine encoded by a single mRNA strand for the prevention of monkeypox. It adopts a concise technical route, which is conducive to quality control and reduction of production costs.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
- CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
- CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
- CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA
- CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted
